Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Richard Monge who wrote (123)	11/6/1997 12:44:00 PM
From: Ken M	Read Replies (1) \| Respond to of 369

>>Ken do you know what the average revenue per procedure will be for URMD and what will be thier gross margin per procedure?<< No idea but it sounds big. Dr. Laurence Klotz Research Director, Division of Surgical Oncology, Toronto Bayview Regional Cancer Center, Toronto, Canada added, "There are approximately 120,000 to 140,000 prostate cancer surgeries performed each year in the United States. The initial results from a Canadian single-centre trial suggest that this technique could enhance the outcome of surgery in many patients." UroMed's patented technology for the CaverMap Surgical Aid system uses state-of-the-art electronics to stimulate and sense the function of the microscopic cavernosal nerves that control erectile function. This system integrates leading edge nerve stimulation technology, ultra-sensitive strain gauge technology and advanced software algorithms with an ergonomic design for use deep in the pelvic cavity. The system includes a reusable portion, a monitor, and a disposable portion for each nerve-sparing prostate cancer surgery. For what it is worth